Anti-hCTLA4-hIgG2

InvivoGen Kontakt z doradcą
Human CTLA4 (ipilimumab) antibody - Human IgG2
Anti-hCTLA4-hIgG2

Anti-hCTLA4-hIgG2 features the constant region of the human IgG2 isotype and the variable region of ipilimumab. Ipilimumab is a fully human IgG1 monoclonal antibody that targets CTLA-4 (also known as CD152), a negative regulator of T cell activation.

By binding CTLA‑4, it inhibits negative signals that physiologically downregulate T cell activation and exerts its therapeutic activity by upregulating the antitumor activity of T lymphocytes [1,2].

In addition, it induces antibody‑dependent cell-mediated cytotoxicity (ADCC) and TNF-α production [3]. Ipilimumab has been approved by the FDA for the treatment of unresectable or metastatic melanoma.

It is undergoing clinical trials for other types of cancers, including lung cancer [4].

Human IgG2 is the second most common antibody present in serum. This isotype is resistant to cleavage by proteolytic enzymes, due to a short hinge region.

Human IgG2 displays low complement-dependent cytotoxicity (CDC) and very low antibody-dependent cell-mediated cytotoxicity (ADCC).

Anti-hCTLA4-hIgG2 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.

References:

  1. Grosso JF. & Jure-Kunkel MN., 2013. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13:5.
  2. Maio M. et al., 2013. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol. 25:166-72.
  3. Laurent S.. et al., 2013. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med. 11:108.
  4. Tomasini P., 2012. Ipilimumab: its potential in non-small cell lung cancer. Ther Adv Med Oncol. 4: 43–50.

Podobne produkty

Anti-hPD1-Ni-hIgG1NQ

Anti-hPD1-Ni-hIgG1NQ

InvivoGen
Więcej
Anti-Dectin-1

Anti-Dectin-1

InvivoGen
Więcej
Anti-hIFN-α8-IgG

Anti-hIFN-α8-IgG

InvivoGen
Więcej